The grades of five Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. Shares of ARIA have increased 21.7% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
This is a strong week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX). The company’s rating climbs to B from the previous week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Investors have pushed the stock price up 13.1% over the past month. Shares of the stock have been trading at an exceptionally rapid pace, up 522.9% from the week prior. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma (NASDAQ:ARRY) improves from a C to a B rating this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. Wall Street has pushed the stock higher by 16.8% over the past month. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Incorporated (NASDAQ:INSM) gets a higher grade this week, advancing from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Wall Street seems to agree with the upgrade and has propelled the stock up 46.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.